Exelixis

EXEL · Nasdaq · United States

Share price · EXEL

$68.29+15.17 (+28.56%) 3M

close as of 2026-11-18 · 24h delayed · vol 1.8M (0.7x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when EXEL's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 30 Oct 2026+4.8%
  2. 6 Aug 2026-7.9%
  3. 3 Aug 2026+3.8%
  4. 3 Jun 2026+6.3%
  5. 8 May 2026+4.2%
  6. 6 May 2026+9.6%
  7. 21 Apr 2026+5.2%
  8. 15 Apr 2026-3.4%
  9. 10 Mar 2026-2.5%
  10. 2 Mar 2026-6.9%

Share of unusual movement by asset

For each asset, the share of EXEL's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Zanzalintinib
events and moves
6shown from 8 days
Cabozantinib
events and moves
1shown from 8 days
Assets with fewer than 8 event days, together—5%
Other company news (earnings, financing, releases naming no asset)—45%
Sessions with no dated event—50%

Assets

(5 total)
5Total Assets
2Approved
1Phase 3 / Filed
2Phase 1–2 / Early
6Diseases
Quick filter:
Showing 5 of 5 assets
Target & Modality
Approved
MET / VEGFR / AXL / RET (multi-kinase)Small molecule
Non-Small Cell Lung CancerRenal Cell CarcinomaHepatocellular CarcinomaProstate Cancer
Clear Cell Renal Cell Carcinoma
Approved
MEK1/2Small molecule
Melanoma
Phase 3
VEGFR2; MET; AXL; MER; TYRO3Small molecule
Non-Small Cell Lung CancerRenal Cell CarcinomaColorectal Cancer
Clear Cell Renal Cell Carcinoma
Phase 1
SIRPα (Signal regulatory protein alpha)Monoclonal antibody
Non-Small Cell Lung Cancer
Phase 1
5T4 (trophoblast glycoprotein, TPBG)Antibody–drug conjugate
Non-Small Cell Lung Cancer

Upcoming events

(11 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (2)
November 2026 (1)
CobimetinibPhase 2Non-small Cell Lung Cancer
Est. primary completion 2026-11-30 · NCT04302025 · CT.gov ↗
What to watch
December 2026 (1)
ZanzalintinibPhase 3Non-Clear Cell Renal Cell Carcinoma
Est. primary completion 2026-12-15 · NCT05678673 · CT.gov ↗
What to watch
2027 (1)
June 2027 (1)
CobimetinibPhase 2/3Non-Small Cell Lung Cancer
Est. primary completion 2027-06-30 · NCT03178552 · CT.gov ↗
What to watch
2028 (5)
February 2028 (2)
CobimetinibPhase 2Ovarian Cancer
Est. primary completion 2028-02-28 · NCT04931342 · CT.gov ↗
What to watch
ZanzalintinibPhase 2Meningioma
Est. primary completion 2028-02-29 · NCT07428616 · CT.gov ↗
What to watch
June 2028 (1)
ZanzalintinibPhase 2Squamous Non-Small Cell Lung Cancer (NSCLC)
Est. primary completion 2028-06-15 · NCT07845786 · CT.gov ↗
What to watch
July 2028 (1)
CobimetinibPhase 3Cancer
Est. primary completion 2028-07-05 · NCT03768063 · CT.gov ↗
What to watch
August 2028 (1)
ZanzalintinibPhase 2/3Head and Neck Squamous Cell Carcinoma
Est. primary completion 2028-08 · NCT06082167 · CT.gov ↗
What to watch
2029 (1)
June 2029 (1)
ZanzalintinibPhase 2/3Pancreatic Neuroendocrine Tumor (pNET), Extra-Pancreatic Neuroendocrine Tumor (epNET)
Est. primary completion 2029-06-30 · NCT06943755 · CT.gov ↗
What to watch
2030 (2)
April 2030 (1)
ZanzalintinibPhase 3Colorectal Cancer
Est. primary completion 2030-04-05 · NCT07750158 · CT.gov ↗
What to watch
May 2030 (1)
Cabozantinib + ZanzalintinibPhase 3Cancer, Renal Cell Carcinoma (RCC), Pancreatic Neuroendocrine Tumors (pNET), Extra-Pancreatic NET (epNET), Hepatocellular Carcinoma (HCC) …
Est. primary completion 2030-05-31 · NCT07620574 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(4)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Coming up

3 December 2026FDA action dateZanzalintinibPDUFA target action date December 3, 2026
US, FDA · Source ↗

Recent

22 June 2026Topline resultZanzalintinibSTELLAR-303 NLM overall survival final analysis
2 February 2026Filing acceptedZanzalintinibFDA accepts zanzalintinib NDA
US, FDA · Exelixis · Source ↗
23 June 2025Topline resultZanzalintinibSTELLAR-303 Phase 3 topline results
Exelixis · Source ↗

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q4$659M$209M$305M+ $587M short-term inv.—$280M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$629M$212M$281M+ $558M short-term inv.—$308M operating cash flowreport ↗
2026-Q2$611M$200M$226M+ $551M short-term inv.—$252M operating cash flowreport ↗
2025-Q4$598M$199M$376M+ $612M short-term inv.—$290M operating cash flowreport ↗
2025-Q3$568M$200M$164M+ $627M short-term inv.—$49M operating cash flowreport ↗
2025-Q2$555M$212M$184M+ $848M short-term inv.—$211M operating cash flowreport ↗
2024-Q3$540M$223M$258M+ $931M short-term inv.—$271M operating cash flowreport ↗
2024-Q2$637M$211M$198M+ $804M short-term inv.—$120M operating cash flowreport ↗
2024-Q1$425M$228M$260M+ $704M short-term inv.—$69M operating cash flowreport ↗
2023-Q3$472M$333M$397M+ $707M short-term inv.—$117M operating cash flowreport ↗
2023-Q2$470M$233M$464M+ $802M short-term inv.—$121M operating cash flowreport ↗
2023-Q1$409M$234M$542M+ $773M short-term inv.—$84M operating cash flowreport ↗
2022-Q3$419M$199M$638M+ $908M short-term inv.—$31M operating cash flowreport ↗
2022-Q2$356M$157M$737M+ $847M short-term inv.—$148M operating cash flowreport ↗
2021-Q4$328M$163M$598M+ $835M short-term inv.—$83M operating cash flowreport ↗
2021-Q3$385M$149M$539M+ $854M short-term inv.—$182M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-FY$2.3B$825M$482M+ $577M short-term inv.—$884M operating cash flowreport ↗

For fiscal 2025, Exelixis reported revenue of $2,320.13M, up 7.0% YoY. R&D spend was $825M, down 9.4% YoY from $910.41M, and cash and equivalents stood at $482.49M. Net income or loss was not disclosed in the provided figures, nor was quarterly net burn.

Operationally, Exelixis noted its ninth consecutive year of annual profitability, with cabozantinib-related net product revenue growth of approximately 17% YoY and royalty growth of approximately 7% YoY. Its lead pipeline asset, zanzalintinib, was under FDA review for certain forms of colorectal cancer and in late-stage development for other indications. CABOMETYX received U.S. approval in March 2025 and EEA/U.K. approvals later in 2025 for previously treated well-differentiated pancreatic and extra-pancreatic neuroendocrine tumors. Early-stage pipeline candidates include XL309, XB010, XB628, and XB371.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$2.2B$910M$217M+ $894M short-term inv.—$700M operating cash flowreport ↗
2023-FY$1.8B$1.0B$263M+ $732M short-term inv.—$333M operating cash flowreport ↗
2022-FY$1.6B$892M$503M+ $807M short-term inv.—$363M operating cash flowreport ↗
2021-FY$988M$548M$321M+ $887M short-term inv.—$209M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 1 purchase ($1.2M), 25 sales ($32.9M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-08-10Beckerle Mary C · directorOpen-market sale9,812$53.66$527KForm 4
2026-06-01Eckhardt Sue Gail · directorOpen-market sale9,812$50.14$492KForm 4
2026-06-01WYSZOMIERSKI JACK L · directorOpen-market sale3,925$50.55$198KForm 4
2026-05-27JOHNSON DAVID EDWARD; Caligan Partners LP · director; directorAward / grant (derivative)19,133——Form 4
2026-05-27POSTE GEORGE · directorAward / grant8,367——Form 4
2026-05-27WYSZOMIERSKI JACK L · directorAward / grant8,367——Form 4
2026-05-27Oliver Bob · directorAward / grant8,367——Form 4
2026-05-27Beckerle Mary C · directorAward / grant8,367——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 691 reporting institutions held 257.4M shares ($10.5B, 105.5% of shares outstanding).

#InstitutionSharesValue
1BlackRock, Inc.30,816,309$1.3B
2RENAISSANCE TECHNOLOGIES LLC13,726,993$588.8M
3FARALLON CAPITAL MANAGEMENT LLC13,111,010$562.3M
4AQR CAPITAL MANAGEMENT LLC13,095,741$561.7M
5VANGUARD PORTFOLIO MANAGEMENT LLC12,085,273$518.3M
6VANGUARD CAPITAL MANAGEMENT LLC11,258,984$482.9M
7STATE STREET CORP10,298,439$441.7M
8FULLER & THALER ASSET MANAGEMENT, INC.8,542,236$366.4M
9GEODE CAPITAL MANAGEMENT, LLC7,795,610$334.4M
10ARROWSTREET CAPITAL, LIMITED PARTNERSHIP4,834,625$207.4M
11Invesco Ltd.4,314,381$185.0M
12DIMENSIONAL FUND ADVISORS LP4,299,597$184.4M
13MORGAN STANLEY4,178,236$179.2M
14Nuveen, LLC3,782,734$162.2M
15D. E. Shaw & Co., Inc.3,603,063$154.5M